BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33870432)

  • 21. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
    Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
    Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection.
    Aspord C; Bruder Costa J; Jacob MC; Dufeu-Duchesne T; Bertucci I; Pouget N; Brevot-Lutton O; Zoulim F; Bourliere M; Plumas J; Leroy V;
    PLoS One; 2016; 11(6):e0156200. PubMed ID: 27281019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.
    Liu YZ; Hou FQ; Ding P; Ren YY; Li SH; Wang GQ
    Virol J; 2012 Nov; 9():274. PubMed ID: 23158844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
    Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
    Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B.
    Gu Y; Lian Y; Zheng Q; Huang Z; Gu L; Bi Y; Li J; Huang Y; Wu Y; Chen L; Huang Y
    BMC Infect Dis; 2020 Jul; 20(1):509. PubMed ID: 32664850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
    Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
    Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss.
    Zimmer CL; Rinker F; Höner Zu Siederdissen C; Manns MP; Wedemeyer H; Cornberg M; Björkström NK
    J Infect Dis; 2018 Apr; 217(10):1656-1666. PubMed ID: 29471497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-γ
    Wu L; Deng H; Feng X; Xie D; Li Z; Chen J; Mo Z; Zhao Q; Hu Z; Yi S; Meng S; Wang J; Li X; Lin B; Gao Z
    J Med Virol; 2024 May; 96(5):e29627. PubMed ID: 38659381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.
    Shiue SJ; Cheng CL; Shiue HS; Chen CN; Cheng SW; Wu LW; Jargalsaikhan G; Chan TS; Lin HY; Wu MS
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of SATB1 expression in regulatory T cells contributes to hepatitis B virus-related chronic liver inflammation.
    Li XF; Tian L; Wang YY; Kong HS; Dong YJ; Zhu QY; Ni Q; Chen Y
    Mol Med Rep; 2015 Jan; 11(1):231-6. PubMed ID: 25338958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.